Cover Image
市場調查報告書

消化性潰瘍:開發中產品分析

Peptic Ulcers - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213113
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
消化性潰瘍:開發中產品分析 Peptic Ulcers - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 58 Pages
簡介

所謂消化性潰瘍是指食道、胃臟內側或小腸上發生的開放性創傷及潰瘍。主要症狀有噁心·嘔吐,及原因不明的體重減輕、食慾變化,腹痛等。主要致病風險要素有吸煙及酒精成癮。主要的治療方法有抗生素和制酸劑,解酸劑,質子幫浦抑制劑等。

本報告提供全球各國治療消化性潰瘍所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

消化性潰瘍概要

治療藥的開發

  • 消化性潰瘍開發中產品:概要
  • 消化性潰瘍開發中產品:比較分析

各企業開發中的消化性潰瘍治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

消化性潰瘍治療藥:開發中的產品一覽(各企業)

消化性潰瘍治療藥的開發企業

  • Ache Laboratorios Farmaceuticos S/A
  • Astellas Pharma Inc.
  • ChoDang Pharm Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • RaQualia Pharma Inc.
  • Sequella, Inc.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • Yooyoung Pharmaceutical Co., Ltd.

消化性潰瘍:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

消化性潰瘍治療藥:開發暫停的產品

消化性潰瘍治療藥:開發中止的產品

消化性潰瘍相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8842IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H2 2016, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 11 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peptic Ulcers Overview
  • Therapeutics Development
  • Pipeline Products for Peptic Ulcers - Overview
  • Peptic Ulcers - Therapeutics under Development by Companies
  • Peptic Ulcers - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Peptic Ulcers - Products under Development by Companies
  • Peptic Ulcers - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Boryung Pharmaceutical Co Ltd
    • ChoDang Pharm Co Ltd
    • Daewoong Pharmaceutical Co Ltd
    • Kukje Pharmaceutical Industry Co Ltd
    • RaQualia Pharma Inc
    • Sequella Inc
    • Sinil Pharmaceutical Co Ltd
    • XuanZhu Pharma Co Ltd
    • Yooyoung Pharmaceutical Co Ltd
  • Peptic Ulcers - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ecabet + ranitidine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lansoprazole + omeprazole) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anaprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholesteryl glucoside - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1386 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KJ-14001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SI-001002 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Gastric Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYD-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peptic Ulcers - Dormant Projects
  • Peptic Ulcers - Discontinued Products
  • Peptic Ulcers - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
      • Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
      • Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
      • Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peptic Ulcers, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Peptic Ulcers - Pipeline by Astellas Pharma Inc, H2 2016
  • Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H2 2016
  • Peptic Ulcers - Pipeline by Sequella Inc, H2 2016
  • Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2016
  • Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peptic Ulcers - Dormant Projects, H2 2016
  • Peptic Ulcers - Dormant Projects (Contd..1), H2 2016
  • Peptic Ulcers - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peptic Ulcers, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top